LE WE PMID CA
Statistics and trial design13Statistik und Studiendesign

Bayesian statistics

Bioinformatics

Biomarker (BASKET)

Case study approach

Data mining

Drug development

Epidemiology

Evidence based medicine

Genomic and genetic analysis

Glucocorticoids

Informed consent

Intention to treat

Kidney (BASKET)

Microarray (Gene expression analysis)

Neoplasia (Study endpoint)

Neoplasia (Tumor biology and immunology)

Network meta analysis

Nicotine

Number needed to treat

Pediatrics

Personalized medicine

Plazebo

Publication issues

Research ethics

Sepsis

Statistics and trial design

Systematic review

Systemic lupus erythematosus

2006  
1
A primer on the use of modern missing-data methods in psychosomatic medicine research.
[16738075] Psychosom Med 68(3): 427-36 (2006)
1997  
2
Multilevel statistical models for psychosomatic research.
[9251152] Psychosom Med 59(4): 350-1 (1997)
1991  
3
2010  
4
The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews.
[20156912] BMJ 340(-): c365 (2010)
2009  
5
Novel methods to deal with publication biases: secondary analysis of antidepressant trials in the FDA trial registry database and related journal publications.
[19666685] BMJ 339(-): b2981 (2009)
2006  
6
Ratio measures in leading medical journals: structured review of accessibility of underlying absolute risks.
[17060338] BMJ 333(7581): 1248 (2006)
2006  
7
Cochrane reviews v industry supported meta-analyses: we should read all reviews with caution.
[17068041] BMJ 333(7574): 916 (2006)
2006  
8
Cochrane reviews v industry supported meta-analyses: has Cochrane really achieved its goals?
[17068040] BMJ 333(7574): 916 (2006)
2006  
9
Cochrane reviews v industry supported meta-analyses: ten questions to assess bias in medical research.
[17068039] BMJ 333(7574): 916-7 (2006)
2006  
10
Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review.
[17028106] BMJ 333(7572): 782 (2006)
2006  
11
The simplest statistical test: how to check for a difference between treatments.
[16735336] BMJ 332(7552): 1256-8 (2006)
2005  
12
Why clinicians are natural bayesians.
[15879401] BMJ 330(7499): 1080-3 (2005)
2005  
13
Readers guide to critical appraisal of cohort studies: 3. Analytical strategies to reduce confounding.
[15860831] BMJ 330(7498): 1021-3 (2005)
2005  
14
Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding.
[15845982] BMJ 330(7497): 960-2 (2005)
2005  
15
Reader's guide to critical appraisal of cohort studies: 1. Role and design.
[15831878] BMJ 330(7496): 895-7 (2005)
2005  
16
Optimal search strategies for retrieving systematic reviews from Medline: analytical survey.
[15619601] BMJ 330(7482): 68 (2005)
2004  
17
Diagnostic tests 4: likelihood ratios.
[15258077] BMJ 329(7458): 168-9 (2004)
2004  
18
2002  
19
Power is indeed irrelevant in interpreting completed studies.
[12458264] BMJ 325(7375): 1304 (2002)
2002  
20
Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis.
[12242181] BMJ 325(7365): 652-4 (2002)
2001  
21
Statistics notes: Analysing controlled trials with baseline and follow up measurements.
[11701584] BMJ 323(7321): 1123-4 (2001)
2001  
22
Sifting the evidence-what's wrong with significance tests?
[11159626] BMJ 322(7280): 226-31 (2001)
2000  
23
The risk of bias from omitted research.
[11021845] BMJ 321(7265): 845-6 (2000)
2000  
24
Statistics notes. The odds ratio.
[10827061] BMJ 320(7247): 1468 (2000)
2000  
25
Scientific, ethical, and logistical considerations in introducing a new operation: a retrospective cohort study from paediatric cardiac surgery.
[10784538] BMJ 320(7243): 1168-73 (2000)
1999  
26
1999  
27
What is meant by intention to treat analysis? Survey of published randomised controlled trials.
[10480822] BMJ 319(7211): 670-4 (1999)
1999  
28
A change in scientific approach: from alternation to randomised allocation in clinical trials in the 1940s.
[10463905] BMJ 319(7209): 572-3 (1999)
1999  
29
Understanding controlled trials. Randomisation methods: concealment.
[10435967] BMJ 319(7206): 375-6 (1999)
1999  
30
Statistics notes: variables and parameters.
[10373171] BMJ 318(7199): 1667 (1999)
1999  
31
Numbers needed to treat derived from meta-analyses--sometimes informative, usually misleading.
[10356018] BMJ 318(7197): 1548-51 (1999)
1999  
32
Statistics notes. Treatment allocation in controlled trials: why randomise?
[10221955] BMJ 318(7192): 1209 (1999)
1998  
33
Survival probabilities (the Kaplan-Meier method).
[9836663] BMJ 317(7172): 1572 (1998)
1998  
34
Confidence intervals for the number needed to treat.
[9804726] BMJ 317(7168): 1309-12 (1998)
1998  
35
Bayesians and frequentists.
[9784463] BMJ 317(7166): 1151-60 (1998)
1998  
36
When placebo controlled trials are essential and equivalence trials are inadequate.
[9748192] BMJ 317(7162): 875-80 (1998)
1998  
37
The intracluster correlation coefficient in cluster randomisation.
[9572764] BMJ 316(7142): 1455 (1998)
1998  
38
What's wrong with Bonferroni adjustments.
[9553006] BMJ 316(7139): 1236-8 (1998)
1998  
39
When can odds ratios mislead?
[9550961] BMJ 316(7136): 989-91 (1998)
1998  
40
Understanding controlled trials. What is a patient preference trial?
[9487173] BMJ 316(7128): 360 (1998)
1998  
41
Meta-analysis. Unresolved issues and future developments.
[9468698] BMJ 316(7126): 221-5 (1998)
1998  
42
Understanding controlled trials. Why are randomised controlled trials important?
[9468688] BMJ 316(7126): 201 (1998)
1998  
43
Spurious precision? Meta-analysis of observational studies.
[9462324] BMJ 316(7125): 140-4 (1998)
1998  
44
Statistics notes. Weighted comparison of means.
[9462320] BMJ 316(7125): 129 (1998)
1997  
45
Meta-analysis. Beyond the grand mean?
[9437284] BMJ 315(7122): 1610-4 (1997)
1997  
46
Papers that summarise other papers (systematic reviews and meta-analyses).
[9310574] BMJ 315(7109): 672-5 (1997)
1997  
47
Statistics notes. Trials randomised in clusters.
[9302962] BMJ 315(7108): 600 (1997)
1997  
48
How to read a paper. Statistics for the non-statistician. II: "Significant" relations and their pitfalls.
[9277611] BMJ 315(7105): 422-5 (1997)
1997  
49
How to read a paper. Statistics for the non-statistician. I: Different types of data need different statistical tests.
[9270463] BMJ 315(7104): 364-6 (1997)
1997  
50
Major journals should peer review trials at protocol stage.
[9193306] BMJ 314(7095): 1691-2 (1997)
1997  
51
Statistics notes. Units of analysis.
[9224131] BMJ 314(7098): 1874 (1997)
1996  
52
Statistics notes. Logarithms.
[8597743] BMJ 312(7032): 700 (1996)
1995  
53
Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons.
[7580713] BMJ 311(7013): 1145-8 (1995)
1994  
54
Identifying relevant studies for systematic reviews.
[7718048] BMJ 309(6964): 1286-91 (1994)
1994  
55
Meta-analysis and its problems.
[7950571] BMJ 309(6957): 789-92 (1994)
1994  
56
Some examples of regression towards the mean.
[7950567] BMJ 309(6957): 780 (1994)
1994  
57
Systematic reviews. Some examples.
[7950526] BMJ 309(6956): 719-21 (1994)
1994  
58
Checklists for review articles.
[8086990] BMJ 309(6955): 648-51 (1994)
1994  
59
Rationale for systematic reviews.
[8086953] BMJ 309(6954): 597-9 (1994)
1985  
60
1983  
61
Statistical guidelines for contributors to medical journals.
[6405856] Br Med J (Clin Res Ed) 286(6376): 1489-93 (1983)
1979  
62
1992  
63
Why clinical trials fail: the hidden assumptions of clinical trials.
[1738874] South Med J 85(2): 117-8 (1992)
2002  
64
The nature of truth: Simpson's Paradox and the limits of statistical data.
[11937652] QJM 95(4): 247-9 (2002)
2000  
65
Confidence limits and the limits of confidence.
[10700483] QJM 93(2): 121-4 (2000)
1999  
66
Bootstrapping: estimating confidence intervals for cost-effectiveness ratios.
[10326078] QJM 92(3): 177-82 (1999)
1998  
67
The significance of non-significance.
[10024920] QJM 91(9): 647-53 (1998)
1998  
68
Likelihood ratios: getting diagnostic testing into perspective.
[9666947] QJM 91(4): 247-58 (1998)
2009  
69
Issues on the selection of non-inferiority margin in clinical trials.
[19302756] Chin Med J (Engl) 122(4): 466-70 (2009)
2008  
70
Imputation methods for missing outcome data in meta-analysis of clinical trials.
[18559412] Clin Trials 5(3): 225-39 (2008)
2005  
71
On criteria for evaluating models of absolute risk.
[15772102] Biostatistics 6(2): 227-39 (2005)
2001  
72
Rethinking historical controls.
[12933631] Biostatistics 2(4): 383-96 (2001)
2004  
73
Twenty statistical errors even you can find in biomedical research articles.
[15311405] Croat Med J 45(4): 361-70 (2004)
2009  
74
Incorporating multiple interventions in meta-analysis: an evaluation of the mixed treatment comparison with the adjusted indirect comparison.
[19772573] Trials 10(-): 86 (2009)
2009  
75
Design, analysis, and presentation of crossover trials.
[19405975] Trials 10(-): 27 (2009)
2008  
76
A review of RCTs in four medical journals to assess the use of imputation to overcome missing data in quality of life outcomes.
[18694492] Trials 9(-): 51 (2008)
2009  
77
Evaluation and recommendations on good clinical laboratory practice guidelines for phase I-III clinical trials.
[19536325] PLoS Med 6(5): e1000067 (2009)
2009  
78
Preventing bias in cluster randomised trials.
[19536323] PLoS Med 6(5): e1000065 (2009)
2008  
79
In the era of systematic reviews, does the size of an individual trial still matter.
[18177203] PLoS Med 5(1): e4 (2008)
2009  
80
A systematic review of the reporting of Data Monitoring Committees' roles, interim analysis and early termination in pediatric clinical trials.
[20003383] BMC Pediatr 9(-): 77 (2009)
2006  
81
Conducting research in individual patients: lessons learnt from two series of N-of-1 trials.
[16984636] BMC Fam Pract 7(-): 54 (2006)
2008  
82
Teaching statistics in biology: using inquiry-based learning to strengthen understanding of statistical analysis in biology laboratory courses.
[18765754] CBE Life Sci Educ 7(3): 317-26 (2008)
2009  
83
Application of multivariate probabilistic (Bayesian) networks to substance use disorder risk stratification and cost estimation.
[20169014] Perspect Health Inf Manag 6(-): 1b (2009)
2009  
84
The use of older studies in meta-analyses of medical interventions: a survey.
[19946395] Open Med 3(2): e62-8 (2009)
2008  
85
Meta-analysis of multi-arm trials using empirical logistic transform.
[19606233] Open Med Inform J 2(-): 112-6 (2008)
2009  
86
Meta-analysis: A brief introduction.
[20443922] Clin Transl Sci 2(5): 374-8 (2009)
2009  
87
Bayesian classification of clinical practice guidelines.
[19667308] Arch Intern Med 169(15): 1431-5 (2009)
2004  
88
Statistical issues in interpreting clinical trials.
[15078496] J Intern Med 255(5): 529-37 (2004)
2004  
89
On the evolution of statistical methods as applied to clinical trials.
[15078495] J Intern Med 255(5): 521-8 (2004)
1997  
90
Interpretation of data from multiple trials: a critical review.
[9104430] J Intern Med 241(3): 177-83 (1997)
2007  
91
Power: not only a matter of numbers, but also of design.
[17587644] Neth J Med 65(6): 197-8 (2007)
2008  
92
Meta-analysis: Its strengths and limitations.
[18595551] Cleve Clin J Med 75(6): 431-9 (2008)
2008  
93
Meta-analyses, metaphysics, and reality.
[18595547] Cleve Clin J Med 75(6): 400 (2008)
1999  
94
Misuse of correlation and regression in three medical journals.
[10396255] J R Soc Med 92(3): 123-8 (1999)
1996  
95
1995  
96
Pitfalls in the interpretation of studies: III.
[7636813] J R Soc Med 88(5): 241-3 (1995)
1995  
97
Pitfalls in the interpretation of studies: I.
[7884763] J R Soc Med 88(1): 2-4 (1995)
2009  
98
Standing on the shoulders of giants: Introduction to systematic reviews and meta-analyses.
[19910604] Can Fam Physician 55(11): 1155-6 (2009)
2001  
99
Hypothesis: the research page. Part 3: Power, sample size, and clinical significance.
[11494932] Can Fam Physician 47(-): 1441-3, 1450-3 (2001)
2008  
100
Tips and tricks in performing a systematic review--chapter 4.
[18307870] Br J Gen Pract 58(547): 136 (2008)
2007  
101
Tips and tricks in performing a systematic review.
[18252086] Br J Gen Pract 57(545): 999 (2007)
2007  
102
Tips and tricks in performing a systematic review.
[17504612] Br J Gen Pract 57(538): 425 (2007)
1996  
103
Is there evidence that megatrials are based on a methodological mistake?
[8978123] Br J Gen Pract 46(412): 688 (1996)
1996  
104
Megatrials are based on a methodological mistake.
[8776917] Br J Gen Pract 46(408): 429-31 (1996)
2004  
105
On the nature and analysis of clustered data.
[15209193] Ann Fam Med 2(3): 199-200 (2004)
1979  
106
The four basic types of evaluation: clinical reviews, clinical trials, program reviews, and program trials.
[109896] Public Health Rep 94(3): 210-5 (1979)
1997  
107
Statistics in the journal--significance, confidence, and all that.
[9254553] Am J Public Health 87(7): 1092-5 (1997)
1991  
108
The importance of assessing the fit of logistic regression models: a case study.
[1746660] Am J Public Health 81(12): 1630-5 (1991)
1984  
109
Consensus methods: characteristics and guidelines for use.
[6380323] Am J Public Health 74(9): 979-83 (1984)
2009  
110
Interpreting results in 2 x 2 tables: part 9 of a series on evaluation of scientific publications.
[20038982] Dtsch Arztebl Int 106(48): 795-800 (2009)
2009  
111
Placebo: misunderstandings and prejudices.
[20019863] Dtsch Arztebl Int 106(46): 751-5 (2009)
2009  
112
Avoiding bias in observational studies: part 8 in a series of articles on evaluation of scientific publications.
[19946431] Dtsch Arztebl Int 106(41): 664-8 (2009)
2009  
113
Descriptive statistics: the specification of statistical measures and their presentation in tables and graphs. Part 7 of a series on evaluation of scientific publications.
[19890414] Dtsch Arztebl Int 106(36): 578-83 (2009)
2009  
114
Systematic literature reviews and meta-analyses: part 6 of a series on evaluation of scientific publications.
[19652768] Dtsch Arztebl Int 106(27): 456-63 (2009)
2009  
115
Requirements and assessment of laboratory tests: Part 5 of a series on evaluation of scientific publications.
[19623307] Dtsch Arztebl Int 106(24): 403-6 (2009)
2009  
116
Study design in medical research: part 2 of a series on the evaluation of scientific publications.
[19568374] Dtsch Arztebl Int 106(11): 184-9 (2009)
2009  
117
Critical appraisal of scientific articles: part 1 of a series on evaluation of scientific publications.
[19562021] Dtsch Arztebl Int 106(7): 100-5 (2009)
2008  
118
Independent predictors from stepwise logistic regression may be nothing more than publishable P values.
[19020117] Anesth Analg 107(6): 1775-8 (2008)
2005  
119
2006  
120
Better methods for meta-analysis available.
[16732124] Anesthesiology 104(6): 1350 (2006)
2000  
121
Current issues in clinical trial design: superiority versus equivalency studies.
[10839934] Anesthesiology 92(6): 1814-20 (2000)
2000  
122
Randomized and nonrandomized clinical studies: statistical considerations.
[10754608] Anesthesiology 92(4): 928-30 (2000)
1993  
123
Pitfalls in performing meta-analysis: I.
[8342859] Anesthesiology 79(2): 405 (1993)
1993  
124
Pitfalls in performing meta-analysis: II.
[8380047] Anesthesiology 79(2): 406-8 (1993)
2008  
125
Bench-to-bedside review: avoiding pitfalls in critical care meta-analysis--funnel plots, risk estimates, types of heterogeneity, baseline risk and the ecologic fallacy.
[18671838] Crit Care 12(4): 220 (2008)
2005  
126
A systematic evaluation of the quality of meta-analyses in the critical care literature.
[16277721] Crit Care 9(5): R575-82 (2005)
2004  
127
Statistics review 13: receiver operating characteristic curves.
[15566624] Crit Care 8(6): 508-12 (2004)
2005  
128
Statistics review 14: Logistic regression.
[15693993] Crit Care 9(1): 112-8 (2005)
2005  
129
Pro/con clinical debate: It is acceptable to stop large multicentre randomized controlled trials at interim analysis for futility. Pro: Futility stopping can speed up the development of effective treatments.
[15693981] Crit Care 9(1): 34-6; discussion 34-6 (2005)
2004  
130
Statistics review 10: further nonparametric methods.
[15153238] Crit Care 8(3): 196-9 (2004)
2004  
131
Statistics review 9: one-way analysis of variance.
[15025774] Crit Care 8(2): 130-6 (2004)
2004  
132
Statistics review 12: survival analysis.
[15469602] Crit Care 8(5): 389-94 (2004)
2004  
133
Statistics review 11: assessing risk.
[15312212] Crit Care 8(4): 287-91 (2004)
2004  
134
Statistics review 8: Qualitative data - tests of association.
[14975045] Crit Care 8(1): 46-53 (2004)
2003  
135
Statistics review 7: Correlation and regression.
[14624685] Crit Care 7(6): 451-9 (2003)
2002  
136
Statistics review 5: Comparison of means.
[12398782] Crit Care 6(5): 424-8 (2002)
2002  
137
Statistics review 4: sample size calculations.
[12225610] Crit Care 6(4): 335-41 (2002)
2002  
138
Statistics review 3: hypothesis testing and P values.
[12133182] Crit Care 6(3): 222-5 (2002)
2002  
139
Statistics review 6: Nonparametric methods.
[12493072] Crit Care 6(6): 509-13 (2002)
2002  
140
Statistics review 2: samples and populations.
[11983040] Crit Care 6(2): 143-8 (2002)
2002  
141
Statistics review 1: presenting and summarising data.
[11940268] Crit Care 6(1): 66-71 (2002)
2005  
142
Advanced statistics: how to determine whether your intervention is different, at least as effective as, or equivalent: a basic introduction.
[15930406] Acad Emerg Med 12(6): 536-42 (2005)
2004  
143
Advanced statistics: understanding medical record review (MRR) studies.
[14759964] Acad Emerg Med 11(2): 187-92 (2004)
2003  
144
Bayesian modeling and real-world problems.
[12837653] Acad Emerg Med 10(7): 780-2 (2003)
2001  
145
Are clinician-investigators Bayesian?
[11733298] Acad Emerg Med 8(12): 1179-81 (2001)
2000  
146
Research fundamentals: statistical considerations in research design: a simple person's approach.
[10691082] Acad Emerg Med 7(2): 194-9 (2000)
1999  
147
Systematic reviews: a logical methodological extension of evidence-based medicine.
[10609928] Acad Emerg Med 6(12): 1255-60 (1999)
1998  
148
Parametric statistical tests: unnecessary assumptions, computers, and the search for the trustworthy p-value.
[9835464] Acad Emerg Med 5(11): 1048-50 (1998)
1997  
149
Recommended guidelines for reviewing, reporting, and conducting research on in-hospital resuscitation: the in-hospital "Utstein style". A statement for health care professionals from the American Heart Association, the European Resuscitation Council, the Heart and Stroke Foundation of Canada, the Australian Resuscitation Council, and the Resuscitation Councils of Southern Africa.
[9189194] Acad Emerg Med 4(6): 603-27 (1997)
2003  
150
Statistical consideration for research.
[12748144] Emerg Med J 20(3): 258-62 (2003)
2003  
151
Designing a research project: randomised controlled trials and their principles.
[12642531] Emerg Med J 20(2): 164-8 (2003)
2003  
152
Observational research methods. Research design II: cohort, cross sectional, and case-control studies.
[12533370] Emerg Med J 20(1): 54-60 (2003)
2002  
153
Overview of research designs.
[12421782] Emerg Med J 19(6): 546-9 (2002)
2001  
154
Article 8. An introduction to hypothesis testing. Non-parametric comparison of two groups-1.
[11435368] Emerg Med J 18(4): 276-82 (2001)
2007  
155
Statistics in review. Part 2: generalised linear models, time-to-event and time-series analysis, evidence synthesis and clinical trials.
[17536991] Crit Care Resusc 9(2): 187-97 (2007)
2007  
156
Statistics in review Part I: graphics, data summary and linear models.
[17352672] Crit Care Resusc 9(1): 81-90 (2007)
2004  
157
Critical care trials: sample size, power and interpretation.
[16556098] Crit Care Resusc 6(4): 239-42 (2004)
2001  
158
Reporting of clinical trials using group sequential methods.
[16573493] Crit Care Resusc 3(3): 146-7 (2001)
2000  
159
Relative risks: relative benefits.
[16597309] Crit Care Resusc 2(4): 244-5 (2000)
2000  
160
The value of the number-needed-to-treat method in antiepileptic drug trials.
[10756410] Epilepsia 41(4): 440-6 (2000)
2004  
161
Methods for analysis of skewed data distributions in psychiatric clinical studies: working with many zero values.
[15229044] Am J Psychiatry 161(7): 1159-68 (2004)
2004  
162
2010  
163
Statistics in experimental cerebrovascular research: comparison of more than two groups with a continuous outcome variable.
[20571520] J Cereb Blood Flow Metab 30(9): 1558-63 (2010)
2005  
164
From the descriptive towards inferential statistics: hundred years since conception of the Student's t-distribution.
[15990717] Neuro Endocrinol Lett 26(3): 167-71 (2005)
2007  
165
Simulation performance checklist generation using the Delphi technique.
[18056208] Can J Anaesth 54(12): 992-7 (2007)
1997  
166
Systematic reviews: the case for rigorous methods and rigorous reporting.
[9104514] Can J Anaesth 44(4): 350-3 (1997)
2007  
167
Consent bias in research: how to avoid it.
[17699171] Heart 93(9): 1024-5 (2007)
2006  
168
2000  
169
Evaluation of large scale clinical trials and their application to usual practice.
[11083755] Heart 84(6): 679-84 (2000)
1988  
170
1989  
171
Understanding investigative clinical trials.
[2651729] J Vasc Surg 9(4): 609-18 (1989)
2006  
172
Methodological issues in cardiovascular epidemiology: the risk of determining absolute risk through statistical models.
[17326336] Vasc Health Risk Manag 2(3): 309-15 (2006)
2007  
173
2007  
174
Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials.
[17488364] Br J Clin Pharmacol 63(5): 595-613 (2007)
2004  
175
2004  
176
The revision of the Declaration of Helsinki: past, present and future.
[15151515] Br J Clin Pharmacol 57(6): 695-713 (2004)
2002  
177
Is intent-to-treat analysis always (ever) enough?
[12207643] Br J Clin Pharmacol 54(2): 203-11 (2002)
2001  
178
Points to consider on switching between superiority and non-inferiority.
[11560553] Br J Clin Pharmacol 52(3): 223-8 (2001)
2001  
179
Switching between superiority and non-inferiority: an introductory note.
[11560552] Br J Clin Pharmacol 52(3): 221 (2001)
2001  
180
Switching between superiority and non-inferiority.
[11560551] Br J Clin Pharmacol 52(3): 219 (2001)
2001  
181
Stopping rules for phase II studies.
[11422011] Br J Clin Pharmacol 51(6): 523-9 (2001)
1979  
182
Validity of cross-over trials.
[552297] Br J Clin Pharmacol 8(1): 5-6 (1979)
1977  
183
2006  
184
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.
[16968952] Pharmacol Rev 58(3): 621-81 (2006)
2005  
185
Regression methods in the empiric analysis of health care data.
[15804208] J Manag Care Pharm 11(3): 240-51 (2005)
2005  
186
Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.
[16278497] Can J Clin Pharmacol 12(3): e254-63 (2005)
2005  
187
Modeling nonlinear dose-response relationships in epidemiologic studies: statistical approaches and practical challenges.
[18648629] Dose Response 3(4): 474-90 (2005)
2005  
188
The causes and effects of socio-demographic exclusions from clinical trials.
[16181564] Health Technol Assess 9(38): iii-iv, ix-x, 1-152 (2005)
2005  
189
Lay public's understanding of equipoise and randomisation in randomised controlled trials.
[15763039] Health Technol Assess 9(8): 1-192, iii-iv (2005)
2005  
190
Issues in data monitoring and interim analysis of trials.
[15763038] Health Technol Assess 9(7): 1-238, iii-iv (2005)
2004  
191
Identification and assessment of ongoing trials in health technology assessment reviews.
[15525479] Health Technol Assess 8(44): iii, 1-87 (2004)
2003  
192
Evaluating non-randomised intervention studies.
[14499048] Health Technol Assess 7(27): iii-x, 1-173 (2003)
2001  
193
Statistical assessment of the learning curves of health technologies.
[11319991] Health Technol Assess 5(12): 1-79 (2001)
2000  
194
Bayesian methods in health technology assessment: a review.
[11134920] Health Technol Assess 4(38): 1-130 (2000)
2000  
195
An introduction to statistical methods for health technology assessment.
[10944742] Health Technol Assess 4(8): i-iv, 1-59 (2000)
1999  
196
Factors that limit the quality, number and progress of randomised controlled trials.
[10683591] Health Technol Assess 3(20): 1-143 (1999)
1998  
197
Systematic reviews of trials and other studies.
[10347832] Health Technol Assess 2(19): 1-276 (1998)
1998  
198
Qualitative research methods in health technology assessment: a review of the literature.
[9919458] Health Technol Assess 2(16): iii-ix, 1-274 (1998)
1998  
199
Choosing between randomised and non-randomised studies: a systematic review.
[9793791] Health Technol Assess 2(13): i-iv, 1-124 (1998)
1998  
200
Consensus development methods, and their use in clinical guideline development.
[9561895] Health Technol Assess 2(3): i-iv, 1-88 (1998)
2006  
201
The (relative) risks of using odds ratios.
[16785380] Arch Dermatol 142(6): 761-4 (2006)
2004  
202
Statistical significance and clinical relevance: the importance of power in clinical trials in dermatology.
[15611433] Arch Dermatol 140(12): 1520-3 (2004)
2004  
203
1990  
204
Statistical methods in microbiology.
[2200604] Clin Microbiol Rev 3(3): 219-26 (1990)
2008  
205
Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia.
[19018610] Clin Infect Dis 47 Suppl 3(-): S249-65 (2008)
2008  
206
Issues in noninferiority trials: the evidence in community-acquired pneumonia.
[18986275] Clin Infect Dis 47 Suppl 3(-): S108-20 (2008)
2005  
207
Basic statistical considerations in virological experiments.
[15613294] J Virol 79(2): 669-76 (2005)
1991  
208
Statistical methods applied in microbiology and epidemiology.
[1752296] Epidemiol Infect 107(3): 467-78 (1991)
2009  
209
Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions.
[19210357] Allergy 64(5): 669-77 (2009)
2002  
210
Statistical issues--significantly important in medical research.
[11929408] Allergy 57(2): 76-82 (2002)
2003  
211
Review of the use of statistics in infection and immunity.
[14638751] Infect Immun 71(12): 6689-92 (2003)
2007  
212
A guide to modern statistical analysis of immunological data.
[17963513] BMC Immunol 8(-): 27 (2007)
1999  
213
Study design and hypothesis testing: issues in the evaluation of evidence from research in nutritional epidemiology.
[10359232] Am J Clin Nutr 69(6): 1315S-1321S (1999)
1997  
214
Statistical design of calibration studies.
[9094919] Am J Clin Nutr 65(4 Suppl): 1187S-1189S (1997)
1997  
215
Regression calibration method for correcting measurement-error bias in nutritional epidemiology.
[9094918] Am J Clin Nutr 65(4 Suppl): 1179S-1186S (1997)
2007  
216
Time-dependent spectral analysis of epidemiological time-series with wavelets.
[17301013] J R Soc Interface 4(15): 625-36 (2007)
2008  
217
Use of game-theoretical methods in biochemistry and biophysics.
[19669489] J Biol Phys 34(1-2): 1-17 (2008)
2007  
218
Computing power in case-control association studies through the use of quadratic approximations: application to meta-statistics.
[17032289] Ann Hum Genet 71(Pt 2): 262-70 (2007)
2009  
219
Factor-analytic models for genotype x environment type problems and structured covariance matrices.
[19284520] Genet Sel Evol 41(-): 21 (2009)
2008  
220
Parameter expansion for estimation of reduced rank covariance matrices.
[18096112] Genet Sel Evol 40(1): 3-24 (2008)
2007  
221
Analysis of the real EADGENE data set: multivariate approaches and post analysis (open access publication).
[18053574] Genet Sel Evol 39(6): 651-68 (2007)
2007  
222
Analysis of the real EADGENE data set: comparison of methods and guidelines for data normalisation and selection of differentially expressed genes (open access publication).
[18053573] Genet Sel Evol 39(6): 633-50 (2007)
2007  
223
The EADGENE Microarray Data Analysis Workshop (open access publication).
[18053572] Genet Sel Evol 39(6): 621-31 (2007)
2008  
224
The role of causal reasoning in understanding Simpson's paradox, Lord's paradox, and the suppression effect: covariate selection in the analysis of observational studies.
[18302750] Emerg Themes Epidemiol 5(-): 5 (2008)
1994  
225
Survey of methods and statistical models used in the analysis of occupational cohort studies.
[8000487] Occup Environ Med 51(10): 649-55 (1994)
2009  
226
Epidemiological methods to tackle causal questions.
[19052115] Int J Epidemiol 38(1): 3-6 (2009)
2009  
227
Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses.
[18824466] Int J Epidemiol 38(1): 287-98 (2009)
2008  
228
Analysis of 2 x 2 tables of frequencies: matching test to experimental design.
[18710887] Int J Epidemiol 37(6): 1430-5 (2008)
2007  
229
Bayesian perspectives for epidemiological research. II. Regression analysis.
[17329317] Int J Epidemiol 36(1): 195-202 (2007)
2006  
230
Regression dilution methods for meta-analysis: assessing long-term variability in plasma fibrinogen among 27,247 adults in 15 prospective studies.
[17148467] Int J Epidemiol 35(6): 1570-8 (2006)
2005  
231
Regression models for twin studies: a critical review.
[16087687] Int J Epidemiol 34(5): 1089-99 (2005)
2005  
232
Commentary: Empirical evidence of attrition bias in clinical trials.
[15649954] Int J Epidemiol 34(1): 87-8 (2005)
2005  
233
Investigating patient exclusion bias in meta-analysis.
[15561753] Int J Epidemiol 34(1): 79-87 (2005)
2005  
234
Regression to the mean: what it is and how to deal with it.
[15333621] Int J Epidemiol 34(1): 215-20 (2005)
2005  
235
Comparison of imputation and modelling methods in the analysis of a physical activity trial with missing outcomes.
[15333619] Int J Epidemiol 34(1): 89-99 (2005)
2004  
236
Mendelian randomization: prospects, potentials, and limitations.
[15075143] Int J Epidemiol 33(1): 30-42 (2004)
2002  
237
Probabilistic record linkage and a method to calculate the positive predictive value.
[12540730] Int J Epidemiol 31(6): 1246-52 (2002)
2002  
238
An overview of relations among causal modelling methods.
[12435780] Int J Epidemiol 31(5): 1030-7 (2002)
2002  
239
Direction and impact of language bias in meta-analyses of controlled trials: empirical study.
[11914306] Int J Epidemiol 31(1): 115-23 (2002)
2002  
240
Being sceptical about meta-analyses: a Bayesian perspective on magnesium trials in myocardial infarction.
[11914302] Int J Epidemiol 31(1): 96-104 (2002)
2002  
241
Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy.
[11914301] Int J Epidemiol 31(1): 88-95 (2002)
2002  
242
Commentary: improving pooled analyses in epidemiology.
[11914300] Int J Epidemiol 31(1): 86-7 (2002)
2002  
243
Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses.
[11914297] Int J Epidemiol 31(1): 72-6 (2002)
2001  
244
Capture-recapture methods--useful or misleading?
[11171841] Int J Epidemiol 30(1): 12-4 (2001)
1999  
245
Simple sample size calculation for cluster-randomized trials.
[10342698] Int J Epidemiol 28(2): 319-26 (1999)
1998  
246
A review of statistical methods for estimating the risk of vertical human immunodeficiency virus transmission.
[10024204] Int J Epidemiol 27(6): 1064-7 (1998)
1997  
247
Regression models for ordinal responses: a review of methods and applications.
[9447413] Int J Epidemiol 26(6): 1323-33 (1997)
1997  
248
2009  
249
The quality of meta-analyses of genetic association studies: a review with recommendations.
[19901000] Am J Epidemiol 170(11): 1333-43 (2009)
2009  
250
Genome-wide association studies, field synopses, and the development of the knowledge base on genetic variation and human diseases.
[19498075] Am J Epidemiol 170(3): 269-79 (2009)
2009  
251
Type of alcoholic beverage and risk of head and neck cancer--a pooled analysis within the INHANCE Consortium.
[19064644] Am J Epidemiol 169(2): 132-42 (2009)
2008  
252
Combining matched and unmatched control groups in case-control studies.
[18836151] Am J Epidemiol 168(10): 1204-10 (2008)
2008  
253
Effect of formal statistical significance on the credibility of observational associations.
[18611956] Am J Epidemiol 168(4): 374-83; discussion 384-90 (2008)
2007  
254
Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles.
[17712019] Am J Epidemiol 166(10): 1203-9 (2007)
2007  
255
Turning the pump handle: evolving methods for integrating the evidence on gene-disease association.
[17804859] Am J Epidemiol 166(8): 863-6 (2007)
2006  
256
Bias in clinical intervention research.
[16443796] Am J Epidemiol 163(6): 493-501 (2006)
2006  
257
Limits to causal inference based on Mendelian randomization: a comparison with randomized controlled trials.
[16410347] Am J Epidemiol 163(5): 397-403 (2006)
2006  
258
Statistical issues in life course epidemiology.
[16306313] Am J Epidemiol 163(1): 84-96 (2006)
2005  
259
Interrater reliability: completing the methods description in medical records review studies.
[15870162] Am J Epidemiol 161(10): 974-7 (2005)
2004  
260
Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker.
[15105181] Am J Epidemiol 159(9): 882-90 (2004)
2002  
261
Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations.
[12181099] Am J Epidemiol 156(4): 300-10 (2002)
2000  
262
Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors.
[11092432] Am J Epidemiol 152(10): 908-11; discussion 912 (2000)
2000  
263
Bias in the evaluation of low-magnitude associations: an empirical perspective.
[10853631] Am J Epidemiol 151(10): 939-45 (2000)
2000  
264
Problems due to small samples and sparse data in conditional logistic regression analysis.
[10707923] Am J Epidemiol 151(5): 531-9 (2000)
1999  
265
Random-effects meta-analyses are not always conservative.
[10472946] Am J Epidemiol 150(5): 469-75 (1999)
1999  
266
Invited commentary: propensity scores.
[10453808] Am J Epidemiol 150(4): 327-33 (1999)
1999  
267
Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis.
[10412966] Am J Epidemiol 150(2): 206-15 (1999)
1999  
268
Presenting statistical uncertainty in trends and dose-response relations.
[10369501] Am J Epidemiol 149(12): 1077-86 (1999)
1998  
269
Prediction and cross-validation of neural networks versus logistic regression: using hepatic disorders as an example.
[9508109] Am J Epidemiol 147(4): 407-13 (1998)
1997  
270
Comparison of effect estimates from a meta-analysis of summary data from published studies and from a meta-analysis using individual patient data for ovarian cancer studies.
[9149663] Am J Epidemiol 145(10): 917-25 (1997)
2003  
271
Matched cohort methods for injury research.
[12923989] Epidemiol Rev 25(-): 43-50 (2003)
2002  
272
2002  
273
Community-based health intervention trials: an overview of methodological issues.
[12119859] Epidemiol Rev 24(1): 72-9 (2002)
2002  
274
Special issues related to randomized trials of primary prevention.
[12119858] Epidemiol Rev 24(1): 67-71 (2002)
2002  
275
Ethics in the design and conduct of clinical trials.
[12119856] Epidemiol Rev 24(1): 54-8 (2002)
2002  
276
2002  
277
Sample size calculations for randomized controlled trials.
[12119854] Epidemiol Rev 24(1): 39-53 (2002)
2002  
278
Analysis of randomized controlled trials.
[12119853] Epidemiol Rev 24(1): 26-38 (2002)
2002  
279
Management and conduct of randomized controlled trials.
[12119852] Epidemiol Rev 24(1): 12-25 (2002)
2000  
280
1999  
281
Spatial analytical methods and geographic information systems: use in health research and epidemiology.
[10682254] Epidemiol Rev 21(2): 143-61 (1999)
1999  
282
Design and interpretation of vaccine field studies.
[10520474] Epidemiol Rev 21(1): 73-88 (1999)
1999  
283
Use of the case-control approach in vaccine evaluation: efficacy and adverse effects.
[10520473] Epidemiol Rev 21(1): 56-72 (1999)
1999  
284
Francis field trial of inactivated poliomyelitis vaccine: background and lessons for today.
[10520470] Epidemiol Rev 21(1): 7-23 (1999)
1998  
285
New techniques for the analysis of cohort studies.
[9762515] Epidemiol Rev 20(1): 122-34 (1998)
1998  
286
Use of computerized record linkage in cohort studies.
[9762514] Epidemiol Rev 20(1): 112-21 (1998)
1998  
287
Growth and development of term children born with low birth weight: effects of genetic and environmental factors.
[9672513] J Pediatr 133(1): 67-72 (1998)
1998  
288
Approaches for conducting large cohort studies.
[9762512] Epidemiol Rev 20(1): 91-9 (1998)
1998  
289
Population-based cohort studies.
[9762511] Epidemiol Rev 20(1): 81-90 (1998)
1998  
290
Quality assurance and quality control in longitudinal studies.
[9762510] Epidemiol Rev 20(1): 71-80 (1998)
1998  
291
Retaining and tracking cohort study members.
[9762509] Epidemiol Rev 20(1): 57-70 (1998)
1998  
292
Exposure measurement in cohort studies: the challenges of prospective data collection.
[9762508] Epidemiol Rev 20(1): 43-56 (1998)
1998  
293
Methodological issues for biomarkers and intermediate outcomes in cohort studies.
[9762507] Epidemiol Rev 20(1): 29-42 (1998)
1998  
294
1997  
295
Ethical and legal issues in genetic epidemiology.
[9360913] Epidemiol Rev 19(1): 163-74 (1997)
1997  
296
DNA banking in epidemiologic studies.
[9360912] Epidemiol Rev 19(1): 156-62 (1997)
1997  
297
Population studies of allele frequencies in single gene disorders: methodological and policy considerations.
[9360902] Epidemiol Rev 19(1): 52-60 (1997)
1997  
298
Evolving methods in genetic epidemiology. IV. Approaches to non-Mendelian inheritance.
[9360901] Epidemiol Rev 19(1): 44-51 (1997)
1997  
299
Evolving methods in genetic epidemiology. III. Gene-environment interaction in epidemiologic research.
[9360900] Epidemiol Rev 19(1): 33-43 (1997)
2003  
300
Number needed to treat (NNT): implication in rheumatology clinical practice.
[12634229] Ann Rheum Dis 62(4): 316-21 (2003)
2004  
301
A surplus of positive trials: weighing biases and reconsidering equipoise.
[15142261] Arthritis Res Ther 6(3): 117-9 (2004)
2008  
302
Systematic review and meta-analysis: when one study is just not enough.
[18178786] Clin J Am Soc Nephrol 3(1): 253-60 (2008)
2007  
303
Practice recommendations based on low, very low, and missing evidence.
[17699379] Clin J Am Soc Nephrol 2(1): 11-2 (2007)
2009  
304
Reporting results of orthopaedic research: confidence intervals and p values.
[19565303] Clin Orthop Relat Res 467(10): 2736-7 (2009)
1993  
305
What price inconclusive clinical trials?
[8323204] Ann R Coll Surg Engl 75(3): 145-6 (1993)
2004  
306
Users' guide to the surgical literature: how to use a systematic literature review and meta-analysis.
[14997929] Can J Surg 47(1): 60-7 (2004)
2002  
307
Users' guide to the surgical literature: how to use an article reporting population-based volume-outcome relationships in surgery.
[11939652] Can J Surg 45(2): 109-15 (2002)
2007  
308
2008  
309
Case-control study design: what, when, and why?
[19057257] J Thorac Oncol 3(12): 1371-2 (2008)
2007  
310
The randomized discontinuation trial: a phase II design to assess growth-inhibitory agents.
[17431101] Mol Cancer Ther 6(4): 1180-5 (2007)
2002  
311
Novel endpoints and design of early clinical trials.
[12401680] Ann Oncol 13 Suppl 4(-): 139-43 (2002)
2002  
312
Designing randomised trials: both large and small trials are needed.
[12401679] Ann Oncol 13 Suppl 4(-): 131-8 (2002)
2002  
313
Evaluation of response: new and standard criteria.
[12401678] Ann Oncol 13 Suppl 4(-): 127-9 (2002)
2003  
314
Survival analysis part IV: further concepts and methods in survival analysis.
[12942105] Br J Cancer 89(5): 781-6 (2003)
2003  
315
Survival analysis Part III: multivariate data analysis -- choosing a model and assessing its adequacy and fit.
[12915864] Br J Cancer 89(4): 605-11 (2003)
2003  
316
Survival analysis part I: basic concepts and first analyses.
[12865907] Br J Cancer 89(2): 232-8 (2003)
1996  
317
Multistage designs for phase II clinical trials: statistical issues in cancer research.
[8883425] Br J Cancer 74(8): 1317-20 (1996)
1995  
318
Sample size: how many patients are necessary?
[7599035] Br J Cancer 72(1): 1-9 (1995)
1993  
319
Intention to treat--who should use ITT?
[8398686] Br J Cancer 68(4): 647-50 (1993)
1993  
320
1993  
321
Current statistical issues in clinical cancer research.
[8353033] Br J Cancer 68(3): 455-6 (1993)
2008  
322
Systematic review of statistical methods used in molecular marker studies in cancer.
[18320601] Cancer 112(8): 1862-8 (2008)
2008  
323
Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review.
[18008363] Cancer 112(2): 228-42 (2008)
2007  
324
The hazards of intermediate endpoints.
[17849427] Cancer 110(9): 1877-9 (2007)
2007  
325
Risks and benefits associated with novel phase 1 oncology trial designs.
[17628485] Cancer 110(5): 1115-24 (2007)
2002  
326
Current concepts in radiation enteritis and implications for future clinical trials.
[12209703] Cancer 95(5): 1151-63 (2002)
2009  
327
Monitoring for lack of benefit: a critical component of a randomized clinical trial.
[19064977] J Clin Oncol 27(4): 629-33 (2009)
2009  
328
Considerations for the use of imaging tools for phase II treatment trials in oncology.
[19276276] Clin Cancer Res 15(6): 1891-7 (2009)
2009  
329
2009  
330
Effective incorporation of biomarkers into phase II trials.
[19276274] Clin Cancer Res 15(6): 1898-905 (2009)
2009  
331
Alternate endpoints for screening phase II studies.
[19276273] Clin Cancer Res 15(6): 1873-82 (2009)
2009  
332
Novel designs and end points for phase II clinical trials.
[19276272] Clin Cancer Res 15(6): 1866-72 (2009)
2008  
333
The ethics of phase 0 oncology trials.
[18559585] Clin Cancer Res 14(12): 3692-7 (2008)
2008  
334
Phase 0 trials: an industry perspective.
[18559583] Clin Cancer Res 14(12): 3683-8 (2008)
2008  
335
The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials.
[18559580] Clin Cancer Res 14(12): 3664-9 (2008)
2007  
336
Trends in the use and role of biomarkers in phase I oncology trials.
[18006773] Clin Cancer Res 13(22 Pt 1): 6719-26 (2007)
2007  
337
Biomarkers in phase I oncology trials: signal, noise, or expensive distraction?
[18006752] Clin Cancer Res 13(22 Pt 1): 6545-8 (2007)
2002  
338
Biostatistical approaches for modeling longitudinal and event time data.
[12171871] Clin Cancer Res 8(8): 2473-4 (2002)
1997  
339
The scientific basis of clinical trials: statistical aspects.
[9815661] Clin Cancer Res 3(12 Pt 2): 2587-90 (1997)
2009  
340
Dose escalation methods in phase I cancer clinical trials.
[19436029] J Natl Cancer Inst 101(10): 708-20 (2009)
1999  
341
Incremental costs of enrolling cancer patients in clinical trials: a population-based study.
[10340904] J Natl Cancer Inst 91(10): 847-53 (1999)
2008  
342
The clinical significance of statistical significance.
[18984874] Oncologist 13(11): 1129-33 (2008)
2009  
343
Editorial on hypothesis and objectives in clinical trials: superiority, equivalence and non-inferiority.
[19302714] Thromb J 7(-): 3 (2009)
1997  
344
Tyranny of the p-value: the conflict between statistical significance and common sense.
[9042074] J Dent Res 76(1): 534-6 (1997)
1990  
345
Statistical management of data in clinical research.
[2101261] Crit Rev Oral Biol Med 1(1): 55-66 (1990)
2005  
346
Synthesizing medical evidence: systematic reviews and metaanalyses.
[16241107] Neurosurg Focus 19(4): E5 (2005)
2008  
347
When is a negative phase II trial truly negative?
[18755930] Am J Respir Crit Care Med 178(6): 554-5 (2008)
2004  
348
The ethical conduct of clinical research involving critically ill patients in the United States and Canada: principles and recommendations.
[15590885] Am J Respir Crit Care Med 170(12): 1375-84 (2004)
2004  
349
Positive clinical trials: understand the control group before implementing the result.
[15151921] Am J Respir Crit Care Med 170(3): 223-6 (2004)
1998  
350
Number needed to treat and relative risk reduction.
[9424990] Ann Intern Med 128(1): 72-3 (1998)
1995  
351
Discordance between meta-analyses and large-scale randomized, controlled trials. Examples from the management of acute myocardial infarction.
[7486471] Ann Intern Med 123(11): 873-7 (1995)
2005  
352
Understanding systematic reviews and meta-analysis.
[16040886] Arch Dis Child 90(8): 845-8 (2005)
2004  
353
GRADE: levels of evidence and grades of recommendation.
[15102650] Arch Dis Child 89(5): 489 (2004)
1995  
354
Statistics from the inside. 16. Multiple regression (2).
[7492177] Arch Dis Child 73(3): 270-4 (1995)
1994  
355
Statistics from the inside. 13. Probability and decisions.
[8067802] Arch Dis Child 71(1): 90-4 (1994)
1993  
356
1993  
357
1992  
358
Statistics from the inside. 7. Regression and correlation.
[1444537] Arch Dis Child 67(10): 1306-9 (1992)
1992  
359
Statistics from the inside. 6. Data structures (continued).
[1626999] Arch Dis Child 67(6): 757-9 (1992)
2007  
360
Documenting research in scientific articles: Guidelines for authors: 3. Reporting multivariate analyses.
[17296672] Chest 131(2): 628-32 (2007)
2007  
361
Documenting research in scientific articles: guidelines for authors: 2. Reporting hypothesis tests.
[17218594] Chest 131(1): 317-9 (2007)
2006  
362
Documenting research in scientific articles: guidelines for authors: reporting research designs and activities.
[17035466] Chest 130(4): 1263-8 (2006)
2002  
363
The design of randomized clinical trials in critically ill patients.
[11948065] Chest 121(4): 1290-300 (2002)
2000  
364
Reality and meta-analyses.
[10988210] Chest 118(3): 835-6 (2000)
2000  
365
Is meta-analysis a metaphysical or a scientific method?
[10988209] Chest 118(3): 832-4 (2000)
1999  
366
Is meta-analysis really meta-physics?
[10453885] Chest 116(2): 539-42 (1999)
2002  
367
Advice on statistical analysis for Circulation Research.
[12386142] Circ Res 91(8): 662-71 (2002)
2008  
368
A primer in longitudinal data analysis.
[18981315] Circulation 118(19): 2005-10 (2008)
2008  
369
Some old and some new statistical tools for outcomes research.
[18711024] Circulation 118(8): 872-84 (2008)
2008  
370
Survival methods: additional topics.
[18519862] Circulation 117(22): 2949-55 (2008)
2008  
371
Methods and limitations of assessing new noninvasive tests: Part II: Outcomes-based validation and reliability assessment of noninvasive testing.
[18506018] Circulation 117(21): 2793-801 (2008)
2008  
372
Methods and limitations of assessing new noninvasive tests: part I: Anatomy-based validation of noninvasive testing.
[18490536] Circulation 117(20): 2684-90 (2008)
2008  
373
2008  
374
Multiple linear regression: accounting for multiple simultaneous determinants of a continuous dependent variable.
[18378626] Circulation 117(13): 1732-7 (2008)
2008  
375
2007  
376
Association studies in an era of too much information: clinical analysis of new biomarker and genetic data.
[17965399] Circulation 116(17): 1866-70 (2007)
2007  
377
What exactly do the trends mean?
[17893285] Circulation 116(13): 1437-9 (2007)
2007  
378
2007  
379
Evaluation of randomized controlled trials.
[17404173] Circulation 115(13): 1819-22 (2007)
2007  
380
Design of randomized controlled trials.
[17339574] Circulation 115(9): 1164-9 (2007)
2007  
381
Use and misuse of the receiver operating characteristic curve in risk prediction.
[17309939] Circulation 115(7): 928-35 (2007)
2007  
382
Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models.
[17283280] Circulation 115(5): 654-7 (2007)
2007  
383
2006  
384
Standards for statistical models used for public reporting of health outcomes: an American Heart Association Scientific Statement from the Quality of Care and Outcomes Research Interdisciplinary Writing Group: cosponsored by the Council on Epidemiology and Prevention and the Stroke Council. Endorsed by the American College of Cardiology Foundation.
[16365198] Circulation 113(3): 456-62 (2006)
2004  
385
The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis.
[15173053] Circulation 109(21): e305-7 (2004)
2004  
386
The clinician as investigator: participating in clinical trials in the practice setting: Appendix 1: fundamentals of study design.
[15173052] Circulation 109(21): e302-4 (2004)
2008  
387
Interpreting results of clinical trials: a conceptual framework.
[18728215] Clin J Am Soc Nephrol 3(5): 1246-52 (2008)
2006  
388
2006  
389
The meta-analysis: supportive or illuminating?
[17107979] Eur Heart J 27(23): 2744-5 (2006)
2006  
390
Progress and problems for randomized clinical trials: from streptomycin to the era of megatrials.
[16870690] Eur Heart J 27(18): 2158-64 (2006)
2006  
391
Limitations of analyses of effectiveness using observational data.
[16785246] Eur Heart J 27(14): 1642-3 (2006)
2004  
392
Interpretation of observational studies.
[15253985] Heart 90(8): 956-60 (2004)
2001  
393
Absolute, attributable, and relative risk in the management of coronary heart disease.
[11302989] Heart 85(5): 491-2 (2001)
2005  
394
Statistical issues in the analysis of neuronal data.
[15985692] J Neurophysiol 94(1): 8-25 (2005)
2007  
395
1993  
396
Statistics in medical research--III. Correlation and regression analysis.
[7996506] J Postgrad Med 39(4): 235-43 (1993)
2007  
397
Data extraction errors in meta-analyses that use standardized mean differences.
[17652297] JAMA 298(4): 430-7 (2007)
2002  
398
How statistical expertise is used in medical research.
[12038922] JAMA 287(21): 2817-20 (2002)
2001  
399
Comparison of evidence of treatment effects in randomized and nonrandomized studies.
[11497536] JAMA 286(7): 821-30 (2001)
1998  
400
Methodology and reports of systematic reviews and meta-analyses: a comparison of Cochrane reviews with articles published in paper-based journals.
[9676681] JAMA 280(3): 278-80 (1998)
1998  
401
Meta-analysis as a clinical tool in nephrology.
[9551387] Kidney Int 53(4): 819-25 (1998)
2008  
402
Clinical research of kidney diseases IV: Standard regression models.
[18182407] Nephrol Dial Transplant 23(2): 475-82 (2008)
2007  
403
P less than .05: what does it really mean?
[17332213] Pediatrics 119(3): 608-10 (2007)
2002  
404
Data and models determine treatment proposals--an illustration from meta-analysis.
[11884693] Postgrad Med J 78(917): 131-4 (2002)
2001  
405
Balancing statistical and clinical significance in evaluating treatment effects.
[11222834] Postgrad Med J 77(905): 201-4 (2001)
1998  
406
Statistics in medicine: some considerations from a clinician's point of view.
[10211346] Postgrad Med J 74(876): 577-8 (1998)
2000  
407
Potential bias in Kaplan-Meier survival analysis applied to rheumatology drug studies.
[10662865] Rheumatology (Oxford) 39(1): 1-2 (2000)
2005  
408
2003  
409
2003  
410
1991  
411
Statistics in respiratory medicine. 3. Scale, parametric methods, and transformations.
[1877042] Thorax 46(7): 536-8 (1991)
1991  
412
Statistics in respiratory medicine. 2. Repeatability and method comparison.
[1858087] Thorax 46(6): 454-6 (1991)
2005  
413
A statistical evaluation of toxicity study designs for the estimation of the benchmark dose in continuous endpoints.
[15483190] Toxicol Sci 84(1): 167-85 (2005)
2001  
414
Statistical issues in the analysis of low-dose endocrine disruptor data.
[11353128] Toxicol Sci 61(2): 201-10 (2001)
2006  
415
Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies.
[17058242] Hepatology 44(5): 1075-82 (2006)
1996  
416
Meta-analysis: an introduction and point of view.
[8666350] Hepatology 23(4): 917-28 (1996)
2008  
417
2004  
418
Prior convictions: Bayesian approaches to the analysis and interpretation of clinical megatrials.
[15172393] J Am Coll Cardiol 43(11): 1929-39 (2004)
2007  
419
The radiology task: Bayesian theory and perception.
[17510249] Br J Radiol 80(954): 389-91 (2007)
2007  
420
Visual grading characteristics (VGC) analysis: a non-parametric rank-invariant statistical method for image quality evaluation.
[16854962] Br J Radiol 80(951): 169-76 (2007)
2004  
421
2002  
422
Statistically engineering the study for success.
[12076904] AJR Am J Roentgenol 179(1): 47-52 (2002)
1988  
423
Statistical techniques for medical decision making: applications to diagnostic radiology.
[3126627] AJR Am J Roentgenol 150(4): 745-50 (1988)
2000  
424
Randomized controlled trials are not appropriate for imaging technology evaluation.
[10914899] J Nucl Med 41(7): 1125-6 (2000)
1998  
425
Statistical analysis: the need, the concept, and the usage.
[9707849] Indian J Ophthalmol 46(1): 51-8 (1998)
1996  
426
Assessment of clinical significance: the number needed to treat.
[8916601] Indian J Ophthalmol 44(2): 113-5 (1996)
2006  
427
How to make clinical decisions from statistics.
[16637974] Clin Exp Optom 89(3): 176-83 (2006)
2008  
428
2005  
429
Epidemiology for ophthalmologists: an introduction to concepts, study designs, and interpreting findings.
[15722322] Br J Ophthalmol 89(3): 378-84 (2005)
2002  
430
The determination of sample size in controlled clinical trials in ophthalmology.
[12185110] Br J Ophthalmol 86(9): 946-7 (2002)
2009  
431
Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses.
[19654195] CMAJ 181(8): 488-93 (2009)
2008  
432
Ethics guidelines for clinical trials to be revised.
[18195278] CMAJ 178(2): 138 (2008)
2007  
433
The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey.
[17420491] CMAJ 176(8): 1091-6 (2007)
2004  
434
Tips for learners of evidence-based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treat.
[15313996] CMAJ 171(4): 353-8 (2004)
2001  
435
Intention-to-treat principle.
[11760981] CMAJ 165(10): 1339-41 (2001)
1995  
436
Basic statistics for clinicians: 1. Hypothesis testing.
[7804919] CMAJ 152(1): 27-32 (1995)
1989  
437
Confidence intervals: from statistical significance to clinical significance.
[2804844] CMAJ 141(9): 881-3 (1989)
2003  
438
1999  
439
Statistical methods for comparative qualitative analysis.
[10352580] Radiology 211(3): 605-7 (1999)
2006  
440
2002  
441
N-of-1 randomized controlled trials ('N-of-1 trials'): singularly useful in geriatric medicine.
[12147558] Age Ageing 31(4): 227-32 (2002)
2010  
442
Recruitment and retention of patients into emergency medicine clinical trials.
[21040112] Acad Emerg Med 17(10): 1104-12 (2010)
2005  
443
Fundamental steps in experimental design for animal studies.
[15810459] Acta Cir Bras 20(1): 2-8 (2005)
2008  
444
Clinical research on new drugs (Phase I). Profile of scientific publications: data from the pre-clinical phase and bioethical aspects.
[19030752] Acta Cir Bras 23(6): 531-5 (2008)
2009  
445
Pitfalls in the design and analysis of paediatric clinical trials: a case of a 'failed' multi-centre study, and potential solutions.
[18826493] Acta Paediatr 98(2): 385-91 (2009)
2011  
446
Mixed method designs in implementation research.
[20967495] Adm Policy Ment Health 38(1): 44-53 (2011)
2011  
447
How helpful are meta-analyses in determining the best therapy of blood diseases?
[21150191] Acta Haematol 125(1-2): 91-101 (2011)
2010  
448
Investigator-initiated trials of targeted oncology agents: why independent research is at risk?
[20133383] Ann Oncol 21(8): 1573-8 (2010)
2010  
449
Looking for efficiency rather than efficacy in randomized controlled trials in oncology.
[20501504] Ann Oncol 21(7): 1391-3 (2010)
2004  
450
Statistical analyses of repeated measures in physiological research: a tutorial.
[14973047] Adv Physiol Educ 28(1-4): 2-14 (2004)
2004  
451
Analogies for understanding statistics.
[15319195] Adv Physiol Educ 28(1-4): 124-5 (2004)
2008  
452
Explorations in statistics: standard deviations and standard errors.
[18794241] Adv Physiol Educ 32(3): 203-8 (2008)
2007  
453
Minimal clinically important improvement/difference (MCII/MCID) and patient acceptable symptom state (PASS): what do these concepts mean?
[17934093] Ann Rheum Dis 66 Suppl 3(-): iii40-1 (2007)
2004  
454
Model-based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in case-control studies.
[15286014] Am J Epidemiol 160(4): 301-5 (2004)
2004  
455
Imputations of missing values in practice: results from imputations of serum cholesterol in 28 cohort studies.
[15229115] Am J Epidemiol 160(1): 34-45 (2004)
2008  
456
Use of multiple imputation in the epidemiologic literature.
[18591202] Am J Epidemiol 168(4): 355-7 (2008)
2004  
457
New applications of statistical tools in plant pathology.
[18943077] Phytopathology 94(9): 999-1003 (2004)
2009  
458
Design and debugging databases for statistical analysis.
[19445866] Allergol Immunopathol (Madr) 37(2): 93-7 (2009)
2008  
459
Issues related to the conduct of systematic reviews: a focus on the nutrition field.
[18996852] Am J Clin Nutr 88(5): 1191-9 (2008)
2010  
460
GRACE principles: recognizing high-quality observational studies of comparative effectiveness.
[20560690] Am J Manag Care 16(6): 467-71 (2010)
2004  
461
Systematic reviews for evidence-based management: how to find them and what to do with them.
[15623270] Am J Manag Care 10(11 Pt 1): 806-12 (2004)
2002  
462
Designing studies to ensure that estimates of test accuracy are transferable.
[11895830] BMJ 324(7338): 669-71 (2002)
2002  
463
What to do about poor clinical performance in clinical trials.
[11850378] BMJ 324(7334): 419-20 (2002)
2002  
464
Peer review of statistics in medical research: the other problem.
[12028986] BMJ 324(7348): 1271-3 (2002)
2011  
465
Multiplicity of data in trial reports and the reliability of meta-analyses: empirical study.
[21878462] BMJ 343(-): d4829 (2011)
2004  
466
What doesn't work and how to show it.
[14988162] BMJ 328(7438): 473 (2004)
2004  
467
Inappropriate use of randomised trials to evaluate complex phenomena: case study of vaginal breech delivery.
[15514356] BMJ 329(7473): 1039-42 (2004)
2003  
468
Strategy for randomised clinical trials in rare cancers.
[12842959] BMJ 327(7405): 47-9 (2003)
2003  
469
Ethics of clinical trials from a bayesian and decision analytic perspective: whose equipoise is it anyway?
[12727776] BMJ 326(7396): 980-1 (2003)
2007  
470
Uncertainty in heterogeneity estimates in meta-analyses.
[17974687] BMJ 335(7626): 914-6 (2007)
2009  
471
Written informed consent and selection bias in observational studies using medical records: systematic review.
[19282440] BMJ 338(-): b866 (2009)
2005  
472
Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors.
[15681569] BMJ 330(7494): 753 (2005)
2005  
473
Standard deviations and standard errors.
[16223828] BMJ 331(7521): 903 (2005)
2008  
474
Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study.
[18316340] BMJ 336(7644): 601-5 (2008)
2006  
475
Further lessons from the TGN1412 tragedy.
[16888292] BMJ 333(7562): 270-1 (2006)
2009  
476
What can we learn from design faults in the Women's Health Initiative randomized clinical trial?
[19583558] Bull NYU Hosp Jt Dis 67(2): 226-9 (2009)
2009  
477
Methods to analyze real-world databases and registries.
[19583553] Bull NYU Hosp Jt Dis 67(2): 193-7 (2009)
2008  
478
Some main problems eroding the credibility and relevance of randomized trials.
[18537784] Bull NYU Hosp Jt Dis 66(2): 135-9 (2008)
2008  
479
How to do human-subjects research if you do not have an institutional review board.
[18812001] Respir Care 53(10): 1362-7 (2008)
2008  
480
Practical tips for working effectively with your institutional review board.
[18812000] Respir Care 53(10): 1354-61 (2008)
2008  
481
Institutional review board consideration of chart reviews, case reports, and observational studies.
[18811999] Respir Care 53(10): 1350-3 (2008)
2008  
482
Protecting vulnerable subjects in clinical research: children, pregnant women, prisoners, and employees.
[18811998] Respir Care 53(10): 1342-9 (2008)
2008  
483
Informed consent: what is it? Who can give it? How do we improve it?
[18811997] Respir Care 53(10): 1337-41 (2008)
2008  
484
The purpose, composition, and function of an institutional review board: balancing priorities.
[18811996] Respir Care 53(10): 1330-6 (2008)
2008  
485
The historical, ethical, and legal background of human-subjects research.
[18811995] Respir Care 53(10): 1325-9 (2008)
2008  
486
The institutional review board and you.
[18811994] Respir Care 53(10): 1324 (2008)
2009  
487
Translating evidence into practice.
[19796420] Respir Care 54(10): 1386-401 (2009)
2008  
488
Dispelling the myths: calling for sex-specific reporting of trial results.
[18452679] Mayo Clin Proc 83(5): 523-5 (2008)
2011  
489
Review and classification of variability analysis techniques with clinical applications.
[21985357] Biomed Eng Online 10(-): 90 (2011)
2011  
490
A note on the use of the generalized odds ratio in meta-analysis of association studies involving bi- and tri-allelic polymorphisms.
[21645382] BMC Res Notes 4(-): 172 (2011)
2009  
491
Optimizing trial design: sequential, adaptive, and enrichment strategies.
[19188520] Circulation 119(4): 597-605 (2009)
2003  
492
An appraisal of multivariable logistic models in the pulmonary and critical care literature.
[12628895] Chest 123(3): 923-8 (2003)
2008  
493
From Delphi to knowledge and comfort: the devil is in the details.
[18460509] Chest 133(5): 1060-2 (2008)
2003  
494
Correlation and simple linear regression.
[12773666] Radiology 227(3): 617-22 (2003)
2008  
495
Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke.
[18349026] Eur Heart J 29(9): 1086-92 (2008)
2009  
496
Need for ethics approval and patient consent in clinical research.
[19286586] Stroke 40(5): 1555-6 (2009)
2007  
497
Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis.
[17272767] Stroke 38(3): 1091-6 (2007)
2006  
498
How to design a clinical in cardiology. The main issues.
[16623360] Rev Port Cardiol 25(1): 105-18 (2006)
2006  
499
Types of clinical studies. Systematic reviews.
[16673653] Rev Port Cardiol 25(2): 233-46 (2006)
2002  
500
Subgroup analysis in therapeutic trials.
[12017805] Rev Port Cardiol 21(3): 339-46 (2002)
2002  
501
Basics of methodologic analysis of therapeutic trials. Part I: Validity of the results.
[12090131] Rev Port Cardiol 21(4): 457-69 (2002)
2002  
502
Intention-to-treat analysis in clinical trials: principles and practical importance.
[12522981] Rev Port Cardiol 21(10): 1191-8 (2002)
2004  
503
Randomization methods in clinical trials.
[15279458] Rev Port Cardiol 23(5): 741-55 (2004)
2008  
504
Evidence-based medicine, systematic reviews, and guidelines in interventional pain management: Part 2: Randomized controlled trials.
[19057624] Pain Physician 11(6): 717-73 (2008)
2005  
505
2009  
506
Evidence-based medicine, systematic reviews, and guidelines in interventional pain management: Part 7: systematic reviews and meta-analyses of diagnostic accuracy studies.
[19935980] Pain Physician 12(6): 929-63 (2009)
2003  
507
2009  
508
An overview of recent developments in genomics and associated statistical methods.
[19805447] Philos Transact A Math Phys Eng Sci 367(1906): 4313-37 (2009)
2010  
509
Development of anti-cancer drugs.
[21034677] Discov Med 10(53): 355-62 (2010)
2011  
510
Quantifying selective reporting and the Proteus phenomenon for multiple datasets with similar bias.
[21479240] PLoS One 6(3): e18362 (2011)
2011  
511
GTI: a novel algorithm for identifying outlier gene expression profiles from integrated microarray datasets.
[21365010] PLoS One 6(2): e17259 (2011)
2011  
512
Three-armed trials including placebo and no-treatment groups may be subject to publication bias: systematic review.
[21655196] PLoS One 6(5): e20679 (2011)
2010  
513
Room for improvement in conducting and reporting non-inferiority randomized controlled trials on drugs: a systematic review.
[21048948] PLoS One 5(10): e13550 (2010)
2010  
514
Obtaining valid laboratory data in clinical trials conducted in resource diverse settings: lessons learned from a microbicide phase III clinical trial.
[21048963] PLoS One 5(10): e13592 (2010)
2010  
515
A generalized formula for converting chi-square tests to effect sizes for meta-analysis.
[20383281] PLoS One 5(4): e10059 (2010)
2007  
516
Statistical reviewers improve reporting in biomedical articles: a randomized trial.
[17389922] PLoS One 2(3): e332 (2007)
2010  
517
Phase III clinical trial development: a process of chutes and ladders.
[21062928] Clin Cancer Res 16(22): 5381-9 (2010)
2010  
518
Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee.
[20215542] Clin Cancer Res 16(6): 1726-36 (2010)
2010  
519
Information needed to conduct first-in-human oncology trials in the United States: a view from a former FDA medical reviewer.
[20215544] Clin Cancer Res 16(6): 1719-25 (2010)
2010  
520
An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.
[20215546] Clin Cancer Res 16(6): 1710-8 (2010)
2010  
521
GCP data quality for early clinical development.
[20215550] Clin Cancer Res 16(6): 1756-63 (2010)
2010  
522
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.
[20215557] Clin Cancer Res 16(6): 1764-9 (2010)
2010  
523
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.
[20215558] Clin Cancer Res 16(6): 1745-55 (2010)
2007  
524
Testing the wrong hypothesis in phase II oncology trials: there is a better alternative.
[17289865] Clin Cancer Res 13(3): 781-2 (2007)
2007  
525
Phase 0 trials: are they ethically challenged?
[17289866] Clin Cancer Res 13(3): 783-4 (2007)
2008  
526
Statistical issues in translational cancer research.
[18829473] Clin Cancer Res 14(19): 5954-8 (2008)
2010  
527
New results will change the paradigm for phase I trials and drug approval.
[20930096] Oncologist 15(10): 1023-5 (2010)
2010  
528
The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology.
[20237212] Oncologist 15 Suppl 1(-): 13-8 (2010)
2010  
529
Combining targeted therapies: practical issues to consider at the bench and bedside.
[20080862] Oncologist 15(1): 37-50 (2010)
2009  
530
Bayesian statistics in oncology: a guide for the clinical investigator.
[19691089] Cancer 115(23): 5371-81 (2009)
2007  
531
Differences between a drug regimen employed in early phase 1 trials and the subsequent use of the agent in routine oncologic practice: a note of caution.
[17879372] Cancer 110(8): 1644-7 (2007)
2009  
532
Central pathology review in multicenter trials and studies: lessons from the nephroblastoma trials.
[19241454] Cancer 115(9): 1977-83 (2009)
2003  
533
Survival analysis part II: multivariate data analysis--an introduction to concepts and methods.
[12888808] Br J Cancer 89(3): 431-6 (2003)
2008  
534
Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials.
[18577549] Rheumatology (Oxford) 47(9): 1367-72 (2008)
2008  
535
Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: a survey of power considerations.
[18495823] Rheumatology (Oxford) 47(7): 1054-7 (2008)
2008  
536
Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve.
[18024533] Clin Chem 54(1): 17-23 (2008)
2010  
537
Corticosteroids for sepsis: registry versus Cochrane systematic review!
[20727225] Crit Care 14(4): 185 (2010)
2010  
538
Delta inflation: a bias in the design of randomized controlled trials in critical care medicine.
[20429873] Crit Care 14(2): R77 (2010)
2005  
539
2005  
540
Registries and registration of clinical trials.
[16382070] N Engl J Med 353(26): 2811-2 (2005)
2004  
541
Clinical trial registration: a statement from the International Committee of Medical Journal Editors.
[15356289] N Engl J Med 351(12): 1250-1 (2004)
2007  
542
Statistics in medicine--reporting of subgroup analyses in clinical trials.
[18032770] N Engl J Med 357(21): 2189-94 (2007)
2010  
543
Sample size calculation in clinical trials: part 13 of a series on evaluation of scientific publications.
[20827353] Dtsch Arztebl Int 107(31-32): 552-6 (2010)
2011  
544
Survival analysis: part 15 of a series on evaluation of scientific publications.
[21475574] Dtsch Arztebl Int 108(10): 163-9 (2011)
2011  
545
Randomized controlled trials-an indispensible part of clinical research.
[22013493] Dtsch Arztebl Int 108(39): 661-2 (2011)
2010  
546
Linear regression analysis: part 14 of a series on evaluation of scientific publications.
[21116397] Dtsch Arztebl Int 107(44): 776-82 (2010)
2010  
547
The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials.
[20467553] Dtsch Arztebl Int 107(16): 279-85 (2010)
2010  
548
The financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication.
[20490338] Dtsch Arztebl Int 107(17): 295-301 (2010)
2003  
549
Inclusion of patients in clinical trial analysis: the intention-to-treat principle.
[14558871] Med J Aust 179(8): 438-40 (2003)
2004  
550
Biostatistics 203. Survival analysis.
[15181518] Singapore Med J 45(6): 249-56 (2004)
2004  
551
Biostatistics 302. Principal component and factor analysis.
[15568116] Singapore Med J 45(12): 558-65, quiz 566 (2004)
2005  
552
Biostatistics 303. Discriminant analysis.
[15678285] Singapore Med J 46(2): 54-61; quiz 62 (2005)
2005  
553
Biostatistics 306. Log-linear models: poisson regression.
[16049606] Singapore Med J 46(8): 377-85; quiz 386 (2005)
2004  
554
Systematic review of statistical methods used to analyze Seattle Angina Questionnaire scores.
[15010742] Can J Cardiol 20(2): 187-93 (2004)
2007  
555
Statistical errors in medical research--a chronic disease?
[17299668] Swiss Med Wkly 137(3-4): 41-3 (2007)
2007  
556
Statistical errors in medical research--a review of common pitfalls.
[17299669] Swiss Med Wkly 137(3-4): 44-9 (2007)
2004  
557
Statistical methods for linking health, exposure, and hazards.
[15471740] Environ Health Perspect 112(14): 1440-5 (2004)
2004  
558
Accounting for historical information in designing experiments: the Bayesian approach.
[15536267] Ann Ist Super Sanita 40(2): 173-9 (2004)
2007  
559
Evidence-based medicine for rare diseases: implications for data interpretation and clinical trial design.
[17387301] Cancer Control 14(2): 160-6 (2007)
2002  
560
Confidence in statistical analysis.
[12453920] Br J Anaesth 89(6): 807-10 (2002)
2003  
561
Misuse of standard error of the mean (SEM) when reporting variability of a sample. A critical evaluation of four anaesthesia journals.
[12644429] Br J Anaesth 90(4): 514-6 (2003)
2007  
562
Using the Bland-Altman method to measure agreement with repeated measures.
[17702826] Br J Anaesth 99(3): 309-11 (2007)
2010  
563
Equivalence and noninferiority testing in anesthesiology research.
[20808211] Anesthesiology 113(4): 779-81 (2010)
2010  
564
Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial.
[20537177] BMC Med Res Methodol 10(-): 54 (2010)
2011  
565
Questions asked and answered in pilot and feasibility randomized controlled trials.
[21846349] BMC Med Res Methodol 11(-): 117 (2011)
2011  
566
Simulation methods to estimate design power: an overview for applied research.
[21689447] BMC Med Res Methodol 11(-): 94 (2011)
2011  
567
2002  
568
Simpson's paradox and calculation of number needed to treat from meta-analysis.
[11860604] BMC Med Res Methodol 2(-): 1 (2002)
2002  
569
Pooling data for number needed to treat: no problems for apples.
[11860605] BMC Med Res Methodol 2(): 2 (2002)
2002  
570
Meta-analysis, Simpson's paradox, and the number needed to treat.
[11860606] BMC Med Res Methodol 2(): 3 (2002)
2002  
571
Markers for early detection of cancer: statistical guidelines for nested case-control studies.
[11914137] BMC Med Res Methodol 2(-): 4 (2002)
2002  
572
Do multiple outcome measures require p-value adjustment?
[12069695] BMC Med Res Methodol 2(-): 8 (2002)
2002  
573
Statistical issues in randomized trials of cancer screening.
[12238954] BMC Med Res Methodol 2(-): 11 (2002)
2010  
574
A systematic review of models to predict recruitment to multicentre clinical trials.
[20604946] BMC Med Res Methodol 10(-): 63 (2010)
2010  
575
What is a pilot or feasibility study? A review of current practice and editorial policy.
[20637084] BMC Med Res Methodol 10(-): 67 (2010)
2011  
576
Calculating unreported confidence intervals for paired data.
[21569392] BMC Med Res Methodol 11(-): 66 (2011)
2011  
577
Parametric methods outperformed non-parametric methods in comparisons of discrete numerical variables.
[21489231] BMC Med Res Methodol 11(-): 44 (2011)
2011  
578
Instrumental variable meta-analysis of individual patient data: application to adjust for treatment non-compliance.
[21510899] BMC Med Res Methodol 11(-): 55 (2011)
2008  
579
Regression toward the mean--a detection method for unknown population mean based on Mee and Chua's algorithm.
[18687143] BMC Med Res Methodol 8(-): 52 (2008)
2008  
580
Advantages of the nested case-control design in diagnostic research.
[18644127] BMC Med Res Methodol 8(-): 48 (2008)
2005  
581
Systems validation: application to statistical programs.
[15649319] BMC Med Res Methodol 5(1): 3 (2005)
2009  
582
Evidence synthesis as the key to more coherent and efficient research.
[19405972] BMC Med Res Methodol 9(-): 29 (2009)
2008  
583
The use of interim data and Data Monitoring Committee recommendations in randomized controlled trial reports: frequency, implications and potential sources of bias.
[18366697] BMC Med Res Methodol 8(-): 12 (2008)
2008  
584
Assessing the order of magnitude of outcomes in single-arm cohorts through systematic comparison with corresponding cohorts: an example from the AMOS study.
[18366683] BMC Med Res Methodol 8(-): 11 (2008)
2008  
585
The impact of consent on observational research: a comparison of outcomes from consenters and non consenters to an observational study.
[18387187] BMC Med Res Methodol 8(-): 15 (2008)
2007  
586
Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
[18199854] Mol Interv 7(6): 325-34 (2007)
2006  
587
What are open-label extension studies for?
[16583468] J Rheumatol 33(4): 642-3 (2006)
2004  
588
Trials are short, disease long: measuring drug utility beyond clinical trials.
[14760785] J Rheumatol 31(2): 205-6 (2004)
2004  
589
Are individual patient trials (n-of-1 trials) in rheumatology worth the extra effort?
[14705210] J Rheumatol 31(1): 8-11 (2004)
2008  
590
Do Lego guns cause crime?: A light-hearted review of case-control, cohort, and RCT study designs.
[19005135] Can Fam Physician 54(11): 1635-6 (2008)
2009  
591
Recruiting issues in community-based studies: some advice from lessons learned.
[19439712] Can Fam Physician 55(5): 557-8 (2009)
2010  
592
Corporate influence over planning and presentation of clinical trials: beauty and the beast.
[20014930] Expert Rev Cardiovasc Ther 8(1): 7-9 (2010)
2002  
593
What makes a good case-control study? Design issues for complex traits such as endometriosis.
[12042253] Hum Reprod 17(6): 1415-23 (2002)
2007  
594
Insights into how to conduct a clinical trial in the UK.
[17911130] J R Soc Med 100(10): 469-72 (2007)
2005  
595
Understanding measures of treatment effect in clinical trials.
[15613512] Arch Dis Child 90(1): 54-6 (2005)
2008  
596
Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review.
[18489611] Br J Clin Pharmacol 66(2): 266-75 (2008)
2011  
597
Significance testing as perverse probabilistic reasoning.
[21356064] BMC Med 9(-): 20 (2011)
2009  
598
What is stochastic resonance? Definitions, misconceptions, debates, and its relevance to biology.
[19562010] PLoS Comput Biol 5(5): e1000348 (2009)
2002  
599
A comparative review of statistical methods for discovering differentially expressed genes in replicated microarray experiments.
[12016052] Bioinformatics 18(4): 546-54 (2002)
2010  
600
Biomarker detection in the integration of multiple multi-class genomic studies.
[19965884] Bioinformatics 26(3): 333-40 (2010)
2005  
601
Classification using partial least squares with penalized logistic regression.
[15531609] Bioinformatics 21(7): 1104-11 (2005)
2008  
602
Implications of clinical trial design on sample size requirements.
[18469326] Schizophr Bull 34(4): 664-9 (2008)
2002  
603
The use of capture-recapture methods in public health.
[12481204] Bull World Health Organ 80(11): 845 (2002)
2002  
604
Using the two-source capture-recapture method to estimate the incidence of acute flaccid paralysis in Victoria, Australia.
[12481205] Bull World Health Organ 80(11): 846-51 (2002)
2011  
605
2010  
606
2009  
607
Voting With their Feet (VWF) endpoint: a meta-analysis of an alternative endpoint in clinical trials, using 5-ASA induction studies in ulcerative colitis.
[19058232] Inflamm Bowel Dis 15(3): 422-8 (2009)
2011  
608
Assessing the benefit: risk ratio of a drug--randomized and naturalistic evidence.
[21842615] Dialogues Clin Neurosci 13(2): 183-90 (2011)
2011  
609
Evaluation of psychiatric interventions in an observational study: issues in design and analysis.
[21842616] Dialogues Clin Neurosci 13(2): 191-8 (2011)
2011  
610
Effectiveness studies: advantages and disadvantages.
[21842617] Dialogues Clin Neurosci 13(2): 199-207 (2011)
2011  
611
A pragmatic view on pragmatic trials.
[21842619] Dialogues Clin Neurosci 13(2): 217-24 (2011)
2011  
612
Clinical trials in the era of personalized oncology.
[22034206] CA Cancer J Clin 61(6): 365-81 (2011)
2010  
613
2002  
614
Screening trials are even more difficult than we thought they were.
[11830599] J Natl Cancer Inst 94(3): 156-7 (2002)
2004  
615
Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice.
[15240782] J Natl Cancer Inst 96(13): 990-7 (2004)
2004  
616
Nontoxicity endpoints in phase I trial designs for targeted, non-cytotoxic agents.
[15240771] J Natl Cancer Inst 96(13): 977-8 (2004)
2011  
617
Reporting of factorial trials of complex interventions in community settings: a systematic review.
[21771302] Trials 12(-): 179 (2011)
2011  
618
Who is the research subject in cluster randomized trials in health research?
[21791064] Trials 12(-): 183 (2011)
2011  
619
The challenges and opportunities of conducting a clinical trial in a low resource setting: the case of the Cameroon mobile phone SMS (CAMPS) trial, an investigator initiated trial.
[21658262] Trials 12(-): 145 (2011)
2011  
620
Using a business model approach and marketing techniques for recruitment to clinical trials.
[21396088] Trials 12(-): 74 (2011)
2011  
621
Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit.
[21418571] Trials 12(-): 81 (2011)
2011  
622
"Flogging dead horses": evaluating when have clinical trials achieved sufficiency and stability? A case study in cardiac rehabilitation.
[21418648] Trials 12(-): 83 (2011)
2011  
623
Standard requirements for GCP-compliant data management in multinational clinical trials.
[21426576] Trials 12(-): 85 (2011)
2011  
624
Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication.
[21612611] Trials 12(-): 134 (2011)
2011  
625
Through the looking glass: understanding non-inferiority.
[21539749] Trials 12(-): 106 (2011)
2011  
626
Practices, patients and (im)perfect data--feasibility of a randomised controlled clinical drug trial in German general practices.
[21457558] Trials 12(-): 91 (2011)
2011  
627
Resources for authors of reports of randomized trials: harnessing the wisdom of authors, editors, and readers.
[21504615] Trials 12(-): 98 (2011)
2011  
628
Ethical issues posed by cluster randomized trials in health research.
[21507237] Trials 12(-): 100 (2011)
2011  
629
Investigator experiences with financial conflicts of interest in clinical trials.
[21226951] Trials 12(-): 9 (2011)
2010  
630
Reporting bias in medical research - a narrative review.
[20388211] Trials 11(-): 37 (2010)
2010  
631
A systematic review of techniques and interventions for improving adherence to inclusion and exclusion criteria during enrolment into randomised controlled trials.
[20178571] Trials 11(-): 17 (2010)
2009  
632
Paying clinicians to join clinical trials: a review of guidelines and interview study of trialists.
[19272166] Trials 10(-): 15 (2009)
2009  
633
The clinically-integrated randomized trial: proposed novel method for conducting large trials at low cost.
[19265515] Trials 10(-): 14 (2009)
2009  
634
Reporting of harm in randomized controlled trials evaluating stents for percutaneous coronary intervention.
[19413903] Trials 10(-): 29 (2009)
2008  
635
Endorsement of the CONSORT Statement by high impact factor medical journals: a survey of journal editors and journal 'Instructions to Authors'.
[18423021] Trials 9(-): 20 (2008)
2009  
636
Stopping randomized trials early for benefit: a protocol of the Study Of Trial Policy Of Interim Truncation-2 (STOPIT-2).
[19580665] Trials 10(-): 49 (2009)
2009  
637
Compliance of clinical trial registries with the World Health Organization minimum data set: a survey.
[19624821] Trials 10(-): 56 (2009)
2010  
638
Selection bias and information bias in clinical research.
[20407272] Nephron Clin Pract 115(2): c94-9 (2010)
2010  
639
Measures of effect in epidemiological research.
[20407271] Nephron Clin Pract 115(2): c91-3 (2010)
2010  
640
Observational studies are complementary to randomized controlled trials.
[19955822] Nephron Clin Pract 114(3): c173-7 (2010)
2011  
641
Are you "tilting at windmills" or undertaking a valid clinical trial?
[21786433] Yonsei Med J 52(5): 701-16 (2011)
2002  
642
Summary for patients. Paying research subjects: a survey of current policies.
[11874330] Ann Intern Med 136(5): I38 (2002)
2010  
643
Aggregating and disaggregating patients in clinical trials and their subgroup analyses.
[20621903] Ann Intern Med 153(1): 51-2 (2010)
2007  
644
Surrogate end points in clinical trials: the case of anti-neutrophil cytoplasm antibody-associated vasculitis.
[17514615] J Nephrol 20(2): 119-29 (2007)
2009  
645
Clinical research in pediatric nephrology: challenges, and strategies to address them.
[19967646] J Nephrol 22(6): 685-93 (2009)
2008  
646
Ordinal logistic regression models: application in quality of life studies.
[18797732] Cad Saude Publica 24 Suppl 4(-): s581-91 (2008)
2009  
647
In silico preclinical trials: methodology and engineering guide to closed-loop control in type 1 diabetes mellitus.
[20144358] J Diabetes Sci Technol 3(2): 269-82 (2009)
2009  
648
Methods for equivalence and noninferiority testing.
[19147090] Biol Blood Marrow Transplant 15(1 Suppl): 120-7 (2009)
2007  
649
A systematic review of the quality of publications reporting coronary artery bypass grafting trials.
[17897515] Can J Surg 50(4): 266-77 (2007)
2004  
650
2005  
651
New methodology in biomedical science: methodological errors in classical science.
[15687745] Medicina (Kaunas) 41(1): 7-16 (2005)
2011  
652
The evolution of phase I trials in cancer medicine: a critical review of the last decade.
[22059910] Chin J Cancer 30(12): 815-20 (2011)
2010  
653
The role of the statistical editor.
[20658048] Rev Bras Psiquiatr 32(2): 102 (2010)
2004  
654
Receiver operating characteristic (ROC) curve: practical review for radiologists.
[15064554] Korean J Radiol 5(1): 11-8 (2004)
2002  
655
Randomised controlled trials in primary care: scope and application.
[12236280] Br J Gen Pract 52(482): 746-51 (2002)
2002  
656
2007  
657
The case of 'protective fever and chest signs': towards a better understanding of general practice databases.
[17727742] Br J Gen Pract 57(540): 523-5 (2007)
2005  
658
N-of-1 trials: an opportunity to tailor treatment in individual patients.
[15808030] Br J Gen Pract 55(512): 171-2 (2005)
2005  
659
N-of-1 trials of quinine efficacy in skeletal muscle cramps of the leg.
[15808032] Br J Gen Pract 55(512): 181-5 (2005)
2009  
660
Methods for analysing cardiovascular studies with repeated measures.
[19949712] Neth Heart J 17(11): 429-33 (2009)
2011  
661
Practical and updated guidelines on performing meta-analyses of non-randomized studies in interventional cardiology.
[21305479] Cardiol J 18(1): 3-7 (2011)
2002  
662
Meta-analyses involving cross-over trials: methodological issues.
[11914310] Int J Epidemiol 31(1): 140-9 (2002)
2002  
663
Effects of adjusting for censoring on meta-analyses of time-to-event outcomes.
[11914304] Int J Epidemiol 31(1): 107-11 (2002)
2010  
664
Statistical methods for the time-to-event analysis of individual participant data from multiple epidemiological studies.
[20439481] Int J Epidemiol 39(5): 1345-59 (2010)
2010  
665
DataSHIELD: resolving a conflict in contemporary bioscience--performing a pooled analysis of individual-level data without sharing the data.
[20630989] Int J Epidemiol 39(5): 1372-82 (2010)
2010  
666
Commentary: like it and lump it? Meta-analysis using individual participant data.
[20660642] Int J Epidemiol 39(5): 1359-61 (2010)
2010  
667
Quality, quantity and harmony: the DataSHaPER approach to integrating data across bioclinical studies.
[20813861] Int J Epidemiol 39(5): 1383-93 (2010)
2008  
668
Critical reading of the statistical data in scientific studies.
[19378522] Rev Bras Anestesiol 58(3): 260-6 (2008)
2012  
669
Standards for reporting randomized controlled trials in medical informatics: a systematic review of CONSORT adherence in RCTs on clinical decision support.
[21803926] J Am Med Inform Assoc 19(1): 13-21 (2012)
2010  
670
Use of statistical analysis in the biomedical informatics literature.
[20064794] J Am Med Inform Assoc 17(1): 3-5 (2010)
2010  
671
How to develop patient-centered research: some perspectives based on surveys among people with rheumatic diseases in Scandinavia.
[20110341] Phys Ther 90(3): 450-60 (2010)
2011  
672
Researchers' experience with project management in health and medical research: results from a post-project review.
[21635721] BMC Public Health 11(-): 424 (2011)
2011  
673
A systematic review of the effect of retention methods in population-based cohort studies.
[21504610] BMC Public Health 11(-): 249 (2011)
2011  
674
Study protocol for a non-inferiority trial of cytisine versus nicotine replacement therapy in people motivated to stop smoking.
[22104038] BMC Public Health 11(-): 880 (2011)
2008  
675
Methodologies used to estimate tobacco-attributable mortality: a review.
[18211696] BMC Public Health 8(-): 22 (2008)
2010  
676
Traditional statistical methods for evaluating prediction models are uninformative as to clinical value: towards a decision analytic framework.
[20172362] Semin Oncol 37(1): 31-8 (2010)
2011  
677
Why hypotheses informed by observation are often wrong: results of randomized controlled trials challenge chronic disease management strategies based on epidemiological evidence.
[21434699] J Manag Care Pharm 17(3): 224-31 (2011)
2009  
678
What should be done about bias and misconduct in clinical trials?
[19236130] J Manag Care Pharm 15(2): 154-60 (2009)
2009  
679
When is a case-control study not a case-control study?
[19247538] J Rehabil Med 41(4): 209-16 (2009)
2005  
680
Clinimetrics in rehabilitation medicine: current issues in developing and applying measurement instruments 1.
[16024474] J Rehabil Med 37(4): 193-201 (2005)
2008  
681
Critical reading of the statistical data in scientific studies.
[19082330] Rev Bras Cir Cardiovasc 23(3): 396-9 (2008)
2009  
682
The use of electronic data capture tools in clinical trials: Web-survey of 259 Canadian trials.
[19275984] J Med Internet Res 11(1): e8 (2009)
2009  
683
Validation of novel imaging methodologies for use as cancer clinical trial end-points.
[19091547] Eur J Cancer 45(2): 290-9 (2009)
2009  
684
Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies.
[19091546] Eur J Cancer 45(5): 741-6 (2009)
2007  
685
Practical Bayesian adaptive randomisation in clinical trials.
[17306975] Eur J Cancer 43(5): 859-66 (2007)
2011  
686
Sequential methods for random-effects meta-analysis.
[21472757] Stat Med 30(9): 903-21 (2011)
2010  
687
One-stage parametric meta-analysis of time-to-event outcomes.
[20963770] Stat Med 29(29): 3030-45 (2010)
2010  
688
Sequential generalized likelihood ratio tests for vaccine safety evaluation.
[20799244] Stat Med 29(26): 2698-708 (2010)
2010  
689
Real longitudinal data analysis for real people: building a good enough mixed model.
[20013937] Stat Med 29(4): 504-20 (2010)
2009  
690
Correcting for multivariate measurement error by regression calibration in meta-analyses of epidemiological studies.
[19222086] Stat Med 28(7): 1067-92 (2009)
2009  
691
A re-evaluation of the 'quantile approximation method' for random effects meta-analysis.
[19016302] Stat Med 28(2): 338-48 (2009)
2009  
692
Systematically missing confounders in individual participant data meta-analysis of observational cohort studies.
[19222087] Stat Med 28(8): 1218-37 (2009)
2009  
693
Choosing an optimal method to combine P-values.
[19266501] Stat Med 28(11): 1537-53 (2009)
2009  
694
Synthesis analysis of regression models with a continuous outcome.
[19326397] Stat Med 28(11): 1620-35 (2009)
2011  
695
Part 2: implementing clinical trials: a review of the attributes of exemplary clinical trial sites.
[21532813] J Oncol Pract 7(1): 61-4 (2011)
2011  
696
Clinical investigator responsibilities.
[21731522] J Oncol Pract 7(2): 124-8 (2011)
2009  
697
Correct use of repeated measures analysis of variance.
[19262072] Korean J Lab Med 29(1): 1-9 (2009)
2007  
698
Approximating the variance of the conditional probability of the state of a hidden Markov model.
[17672820] Stat Appl Genet Mol Biol 6(-): Article 18 (2007)
2008  
699
Issues in outcomes research: an overview of randomization techniques for clinical trials.
[18345348] J Athl Train 43(2): 215-21 (2008)
2010  
700
Adaptive design clinical trials: Methodology, challenges and prospect.
[20927243] Indian J Pharmacol 42(4): 201-7 (2010)
2002  
701
Some general points in estimating heterogeneity variance with the DerSimonian-Laird estimator.
[12933591] Biostatistics 3(4): 445-57 (2002)
2010  
702
Bayesian inference for generalized linear mixed models.
[19966070] Biostatistics 11(3): 397-412 (2010)
2009  
703
A unification of models for meta-analysis of diagnostic accuracy studies.
[19039031] Biostatistics 10(1): 201-3 (2009)
2008  
704
An alternative model for bivariate random-effects meta-analysis when the within-study correlations are unknown.
[17626226] Biostatistics 9(1): 172-86 (2008)
2011  
705
Adaptive designs in clinical trials.
[21584178] Perspect Clin Res 2(1): 23-7 (2011)
2011  
706
Intention-to-treat concept: A review.
[21897887] Perspect Clin Res 2(3): 109-12 (2011)
2011  
707
A review for clinical outcomes research: hypothesis generation, data strategy, and hypothesis-driven statistical analysis.
[21359904] Surg Endosc 25(7): 2254-60 (2011)
2008  
708
A clinician's guide to statistical methods in urologic oncology.
[18452824] Urol Oncol 26(3): 299 (2008)
2011  
709
Methodological quality of test accuracy studies included in systematic reviews in obstetrics and gynaecology: sources of bias.
[21426545] BMC Womens Health 11(-): 7 (2011)
2011  
710
The quality of reporting of primary test accuracy studies in obstetrics and gynaecology: application of the STARD criteria.
[21429185] BMC Womens Health 11(-): 8 (2011)
2011  
711
Multiple treatment comparison meta-analyses: a step forward into complexity.
[21750628] Clin Epidemiol 3(-): 193-202 (2011)
2008  
712
Analysis of variance: is there a difference in means and what does it mean?
[17936790] J Surg Res 144(1): 158-70 (2008)
2010  
713
Missing data analysis using multiple imputation: getting to the heart of the matter.
[20123676] Circ Cardiovasc Qual Outcomes 3(1): 98-105 (2010)
2002  
714
Regulatory issues for clinical trials in humans.
[12119857] Epidemiol Rev 24(1): 59-66 (2002)
2010  
715
Summarizing historical information on controls in clinical trials.
[20156954] Clin Trials 7(1): 5-18 (2010)
2009  
716
Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center.
[19528130] Clin Trials 6(3): 205-16 (2009)
2005  
717
Systematic evaluation and comparison of statistical tests for publication bias.
[16276033] J Epidemiol 15(6): 235-43 (2005)
2010  
718
An introduction to epidemiologic and statistical methods useful in environmental epidemiology.
[20431236] J Epidemiol 20(3): 177-84 (2010)
2006  
719
2010  
720
A guide to organizing a multicenter clinical trial.
[20375760] Plast Reconstr Surg 126(2): 515-23 (2010)
2008  
721
Adjusted estimates for time-to-event endpoints.
[18791867] Lifetime Data Anal 14(4): 484-95 (2008)
2008  
722
Inference for outcome probabilities in multi-state models.
[18791824] Lifetime Data Anal 14(4): 405-31 (2008)
2011  
723
Review of the methods of determination of directed connectivity from multichannel data.
[21298355] Med Biol Eng Comput 49(5): 521-9 (2011)
2010  
724
Modelling the cumulative risk of a false-positive screening test.
[20356857] Stat Methods Med Res 19(5): 429-49 (2010)
2009  
725
Multi-state models for the analysis of time-to-event data.
[18562394] Stat Methods Med Res 18(2): 195-222 (2009)
2010  
726
A global sensitivity test for evaluating statistical hypotheses with nonidentifiable models.
[19645705] Biometrics 66(2): 558-66 (2010)
2011  
727
The use and abuse of multiple outcomes in randomized controlled depression trials.
[21185405] Contemp Clin Trials 32(2): 299-304 (2011)
2010  
728
Classical and modern measurement theories, patient reports, and clinical outcomes.
[20129315] Contemp Clin Trials 31(1): 1-3 (2010)
2009  
729
Role of animal studies in the design of clinical trials.
[19478492] Front Neurol Neurosci 25(-): 10-33 (2009)
2010  
730
Censoring in clinical trials: review of survival analysis techniques.
[20922095] Indian J Community Med 35(2): 217-21 (2010)
2008  
731
Clinical research methodology I: introduction to randomized trials.
[18222393] J Am Coll Surg 206(2): 361-9 (2008)
2003  
732
How to ... do a randomized controlled trial.
[14634173] J Orthod 30(4): 337-41 (2003)
2010  
733
CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials.
[21350618] J Pharmacol Pharmacother 1(2): 100-7 (2010)
2011  
734
Moving beyond traditional null hypothesis testing: evaluating expectations directly.
[21713172] Front Psychol 2(-): 24 (2011)
2009  
735
Classification and error estimation for discrete data.
[20436873] Curr Genomics 10(7): 446-62 (2009)
2010  
736
Statistical issues in longitudinal data analysis for treatment efficacy studies in the biomedical sciences.
[20588256] Mol Ther 18(9): 1724-30 (2010)
2011  
737
Laboratory and software applications for clinical trials: the global laboratory environment.
[22074278] Bioanalysis 3(21): 2381-4 (2011)
2007  
738
Understanding linear and logistic regression analyses.
[17391582] CJEM 9(2): 111-3 (2007)
2008  
739
Incorporation bias in studies of diagnostic tests: how to avoid being biased about bias.
[18371254] CJEM 10(2): 174-5 (2008)
2010  
740
Developing and Testing a Tool for the Classification of Study Designs in Systematic Reviews of Interventions and Exposures
[21433333] (): (2010)
2010  
741
The noninferiority trial: don't don't do it.
[21087412] Am J Transplant 10(12): 2571-3 (2010)
2010  
742
The attitudes of 1066 patients with cancer towards participation in randomised clinical trials.
[21119659] Br J Cancer 103(12): 1801-7 (2010)
2010  
743
Categorical data analysis in experimental biology.
[20826130] Dev Biol 348(1): 3-11 (2010)
2010  
744
Individual (N-of-1) trials can be combined to give population comparative treatment effect estimates: methodologic considerations.
[20863658] J Clin Epidemiol 63(12): 1312-23 (2010)
2011  
745
Demystify statistical significance--time to move on from the p value to bayesian analysis.
[21131578] J Natl Cancer Inst 103(1): 2-3 (2011)
2010  
746
NCI's clinical trial system: efficiencies grow, debate goes on.
[21088280] J Natl Cancer Inst 102(23): 1750-1, 1755 (2010)
2010  
747
Biomarker-adaptive clinical trial designs.
[21142910] Pharmacogenomics 11(12): 1679-82 (2010)
2010  
748
Observational studies: cohort and case-control studies.
[20697313] Plast Reconstr Surg 126(6): 2234-42 (2010)
2010  
749
Handling missing data in randomized experiments with noncompliance.
[20379779] Prev Sci 11(4): 384-96 (2010)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.



  • Statistik und Studiendesign

  • The BDOM Bibliographic Dictionary of Medicine is a curated collection of free medical articles tagged to concepts.
    Contents until 2011 are reviews from PubMed, contents flagged 'PMC' are regular articles from PubMed Central.
    Search BDOM
    Nephrology Collection
    Radiology Locator

    PubMedCentral monthly collection of free medical articles by major subject

    The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia